Hum. Reprod. Advance Access published online on March 14, 2006
Human Reproduction, doi:10.1093/humrep/del030
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Division of Reproductive Medicine, Department of Obstetrics and Gynaecology, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands
* To whom correspondence should be addressed. BACKGROUND: The aim of this study was to assess the non-inferiority of an oral contraceptive (OC)-pretreated cetrorelix regimen and a buserelin regimen in IVF/ICSI patients treated with r-hFSH in terms of total number of oocytes retrieved. METHODS: Multicentre, randomized study. One hundred and eighty two patients were randomized to receive cetrorelix with OC pretreatment (n = 91) or to receive buserelin (n = 91). The cetrorelix group started with daily OCs on cycle day 5 and continued for 21-28 days. Cetrorelix (0.25 mg) was given daily from stimulation day 6 up to and including the day of r-hCG administration. The buserelin group started with buserelin (500 µg/day) for at least 10 days until down-regulation was achieved, after which the dose was reduced to daily 200 µg up to and including the day of r-hCG administration. r-hFSH was started in both groups on a Friday, in the cetrorelix group 5 days after the last OC pill intake. Both regimens were followed by a standard IVF or ICSI procedure. The primary efficacy endpoint was the number of oocytes retrieved per patient. RESULTS: Number of oocytes, cancellation rates, r-hFSH requirements, number of oocyte retrievals during the weekend or public holiday and number of pregnancies were similar in both groups. Both treatment regimens were well tolerated. CONCLUSIONS: Cetrorelix pretreated with OCs resulted in similar number of oocytes retrieved compared with a long buserelin protocol. Both regimens were well tolerated and allowed scheduling of the oocyte retrieval, with only small number of retrievals falling on a weekend or public holiday.
Received October 24, 2005
Revised January 1, 2006
Accepted January 11, 2006
Article
Cetrorelix in an oral contraceptive-pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r-hFSH: a randomized, multicentre, phase IIIb study
J.A. Huirne 1,
J.N. Hugues 2,
C. Pirard 3,
F. Fischl 4,
J.C. Sage 5,
J.L. Pouly 6,
A. Obruca 7,
D.M. Braat 8,
A.C.D. van Loenen 1,
and
C.B. Lambalk 1 *
2 Hôpital Jean Verdier, Reproductive Medicine Center, University Paris XIII, Paris, France
3 Universite Catholique de Louvain, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium
4 Allgemeines Krankenhaus, Universitätsklinik für Frauenheilkunde Abteilung Gynäkologischen Endocrinologie und Reproduktions Medicin Spitalgasse 23, Vienna, Austria
5 Tour Belledonne, Boulevard Maréchal Leclerc 23, Grenoble
6 Polyclinique Hotel Dieu, Boulevard Charles-de-Gaulle 13, Clermont-Ferrand, France
7 Kinderwunschzentrum Wien, Lazarettgasse 16-18, Vienna, Austria
8 University Hospital Nijmegen, AZ St Radboud, Obstetrecs-Gynaecology, Geert Grootenplein Zuid 1b, GA Nijmegen, The Netherlands
C.B. Lambalk, E-mail: cb.lambalk{at}vumc.nl
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J.A. Huirne, R. Homburg, and C.B. Lambalk Are GnRH antagonists comparable to agonists for use in IVF? Hum. Reprod., November 1, 2007; 22(11): 2805 - 2813. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Cedrin-Durnerin, B. Bstandig, I. Parneix, V. Bied-Damon, C. Avril, C. Decanter, and J.N. Hugues Effects of oral contraceptive, synthetic progestogen or natural estrogen pre-treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol Hum. Reprod., January 1, 2007; 22(1): 109 - 116. [Abstract] [Full Text] [PDF]
|
|